SecBot SecBot
SECBOTREPLAY Home › Report › XNCR

XNCR · Xencor Inc

Xencor Inc · 8-K filed Mar 4, 2026 at 16:02 ET

At the news

BEARISHIMPACT 8/10

8-K filed Mar 4, 2026 at 16:02 ET

Xencor Inc. announced that Alexion Pharmaceuticals disputes its obligation to pay U.S. royalties on Ultomiris sales, potentially forfeiting $100-120 million in expected revenue through 2028. Xencor disagrees with Alexion's position and is evaluating its options, while maintaining its cash guidance of $380-400 million by end-2026 and sufficient runway into mid-2028.

  • Alexion Pharmaceuticals disputes obligation to pay U.S. royalties on Ultomiris sales and will not make future U.S. payments
  • Xencor expected $100-120 million in additional U.S. royalties through 2028 based on patent issuance
  • Xencor disagrees with Alexion's position and is evaluating its options
  • Xencor maintains cash guidance of $380-400 million at end-2026 and sufficient runway into mid-2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access